News & Updates

A real-world study during Hong Kong’s Omicron BA.2.2 wave has shown that viral burden rebound is uncommon in hospitalized COVID-19 patients not requiring supplemental oxygen on admission, regardless of whether they were treated with nirmatrelvir/ritonavir or molnupiravir. However, immunocompromised patients, regardless of oral antiviral use, are more likely to have viral burden rebound.

Mirabegron appears to be as good as vibegron in the treatment of overactive bladder (OAB) in postmenopausal women, with both drugs helping improve symptoms and the parameters of voiding diary, according to a study.

Human papillomavirus (HPV) infection appears to be a risk factor for cardiovascular diseases (CVDs), suggests a recent study. However, women vaccinated against HPV are protected against such risk.

The decision to withdraw life-sustaining therapy (WLST) among acute hospitalized stroke patients is determined by several factors, including age, race, level of consciousness, state region, insurance status, ambulation status at baseline, and stroke centre type, suggests a study presented at ISC 2023.

In a 78-week study, computerized games and crossword puzzles had no differential impact on within-network DMN* functional connectivity (FC) in individuals with mild cognitive impairment (MCI) who are at high risk of developing Alzheimer’s disease (AD). However, crosswords appear to have a slight advantage over the other in other aspects.

The combination of olaparib plus abiraterone in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) appears to show a consistent trend toward overall survival (OS) benefit, according to the results of the final prespecified analysis of the phase III PROpel study presented at ASCO GU 2023.

Success rates of clinical trials in gastric cancer tend to improve with the use of implementing biomarkers, receptor-targeted therapies, and biologics in clinical development, suggests a recent study.